Notice: amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `pre_get_posts` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the theme with slug `publisher` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/runcloud/webapps/techilive/wp-includes/functions.php on line 5313
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight - TechiLive.in

Cushing’s Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight

0

Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) — Cushing’s Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight

Levoketoconazole is expected to emerge as a potential therapy owing to its novelty and oral RoA, thus expected to gain maximum Cushing’s Syndrome patient pool.  

DelveInsight’s Cushing’s Syndrome Pipeline Insights report offers a detailed picture of the emerging therapies expected to enter the Cushing’s Syndrome market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Cushing’s Syndrome domain.

Some of the key highlights of the Cushing’s Syndrome Pipeline report:

  • Cushing’s Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and 10+ key therapies.
  • Cushing’s Syndrome pipeline comprises Relacorilant (Corcept Therapeutics), Levoketoconazole (Strongbridge Biopharma), CRN-04894 (Crinetics Pharmaceuticals), and several others expected to get launched in the next decade. 
  • Some of the key companies developing therapies for the treatment of Cushing’s Syndrome are Crinetics Pharmaceuticals; Corcept Therapeutics; Strongbridge Biopharma; Orphagen Pharmaceuticals; AstraZeneca; Sparrow Pharmaceuticals; and Cyclacel Pharmaceuticals, among others.
  • Out of all the emerging therapies, Levoketoconazole ((Strongbridge Biopharma) is expected to capture the maximum patient pool. Levoketoconazole is a novel oral steroidogenesis inhibitor. It has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing’s Syndrome.
  • Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body’s other hormone receptors. The drug is currently in phase 3 of the development stage for the treatment of Cushing’s Syndrome.
  • Roscovitine, or seliciclib, is an oral anticancer agent, acting as an inhibitor of the cyclin-dependent kinases (CDKs) family. The drug is currently in phase 2 of the development stage for the treatment of Cushing’s Syndrome.

Request for Sample to know more about the therapies that are set to grab maximum patient pool @ Cushing’s Syndrome Emerging Therapies and Forecast 

Cushing’s Syndrome, also known as hypercortisolism, is a rare hormonal disorder caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol. It mostly affects people of age group aged 20 to 50.  The condition can be further divided into two categories, namely, adrenocorticotropic hormone (ACTH)-dependent and ACTH-independent. 

Symptoms of Cushing’s Syndrome include weight gain, thin arms and legs, a round face, increased fat around the base of the neck, fatty hump between the shoulders, easy bruising, and so on. 

For more information on emerging drugs, visit Cushing’s Syndrome Pipeline Analysis 

Cushing’s Syndrome Pipeline Drugs 

Drug Company Clinical Phase MoA RoA
CRN-04894 Crinetics
Pharmaceuticals
Phase I Melanocortin type 2 receptor antagonists Oral
Relacorilant Corcept Therapeutics Phase III Glucocorticoid receptor antagonists Oral
Levoketoconazole Strongbridge
Biopharma
Preregistration 14-alpha demethylase inhibitors; Steroid 11-beta-hydroxylase inhibitors Oral
Seliciclib Cyclacel Pharmaceuticals Phase II Cyclin-dependent kinase 9 and 2 inhibitors Oral

Request for Sample to know more @ Cushing’s Syndrome Pipeline Analysis, Key Companies and Futuristic Trends 

Cushing’s Syndrome Therapeutic Assessment 

The Cushing’s syndrome Pipeline report proffers detailed insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.

By Product Type

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Small Molecule 
  • Gene Therapy
  • Stem Cell Therapy

By Route of Administration

  • Intravenous
  • Inhalation
  • Oral
  • Subcutaneous 

By Mechanism of Action

  • Glucocorticoid receptor antagonists
  • 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
  • Steroid 11-beta-hydroxylase inhibitors
  • Melanocortin type 2 receptor antagonists
  • Cyclin-dependent kinase 9 and 2 inhibitors

By Targets

  • Melanocortin type 2 receptor
  • Multiple Kinase 
  • 11-beta-hydroxysteroid dehydrogenase type 1
  • Glucocorticoid receptor

Get in touch with our Business executive for Informative Business Decisions, Licensing Services  and Consulting Solutions 

Scope of the Report

Coverage: Global
Key Players: Crinetics Pharmaceuticals; Corcept Therapeutics; Strongbridge Biopharma; Orphagen Pharmaceuticals; AstraZeneca; Sparrow Pharmaceuticals; and Cyclacel Pharmaceuticals among others.
Key Cushing’s Syndrome Pipeline Therapies: CRN-04894; Relacorilant; Levoketoconazole; OR 907; AZD 4017; SPI-62; and Seliciclib among others.

Reach out @ Cushing’s Syndrome Pipeline: Novel therapies and emerging technologies 

Table of Contents 

1 Report Introduction
2 Cushing’s Syndrome Overview
3 Cushing’s Syndrome Current Treatment Patterns
4 Cushing’s Syndrome – DelveInsight’s Analytical Perspective
5 Cushing’s Syndrome Pipeline Therapeutic Assessment
6 In-depth Commercial Cushing’s Syndrome Pipeline Assessment
7 Cushing’s Syndrome Collaboration Deals
8 Late Stage Cushing’s Syndrome Pipeline Products (Phase III and Preregistration)
9 Mid-Stage Cushing’s Syndrome Pipeline Products (Phase II)
10 Pre-clinical and Discovery Stage Cushing’s Syndrome Pipeline Products
11 Dormant Cushing’s Syndrome Pipeline Products
12 Inactive Cushing’s Syndrome Pipeline Products
13 Cushing’s Syndrome Discontinued Products
14 Cushing’s Syndrome Key Companies
15 Cushing’s Syndrome Key Products
16  Cushing’s Syndrome Dormant and Discontinued Products
17 Cushing’s Syndrome Unmet Needs
18 Cushing’s Syndrome Market Drivers and Barriers
20 Cushing’s Syndrome Future Perspectives and Conclusion
21 Cushing’s Syndrome Pipeline Analyst Views
22 Appendix

Visit to know more of what’s covered @ Cushing’s Syndrome Emerging Therapies 

Related Reports
Cushing’s Syndrome Market
DelveInsight’s “Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report.

Endogenous Cushings Syndrome Market
DelveInsight’s “Endogenous Cushing’s Syndrome – Market Insights, Epidemiology, and Market Forecast-2030” report.

Endometriosis Pain Market
DelveInsight’s “Endometriosis Pain – Market Insights, Epidemiology, and Market Forecast-2030” report.

Dyslipidemia Market
DelveInsight’s “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030” report

Familial Hypercholesterolemia Market Report
DelveInsight’s ‘Familial Hypercholesterolemia (FH) -Market Insights, Epidemiology and Market Forecast– 2030‘ report.

Follitropin Alfa Biosimilar Insight
DelveInsight’s, “Follitropin alfa– Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Follitropin alfa Biosimilars landscape.

Interferon Biosimilar Insight
DelveInsight’s, “Interferon– Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. 

Isocitrate Dehydrogenase Idh Inhibitors Competitive Landscape Market And Pipeline Analysis- 2020

Related Posts 

Healthcare Delivery Systems: Kow how the technological revolution has transformed Healthcare Delivery Systems

Hyperkalemia Cocktail: Key companies working in the Hyperkalemia market are Zeria Pharmaceutical/Vifor Pharma and Ardelyx.

Marijuana Clinical Trials: Analysis into key Marijuana Clinical Trials for indications such as Chronic Pain, Epilepsy, Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Huntington’s Disease, Irritable Bowel Syndrome, Schizophrenia, Psychosis, Glaucoma, and so many others.

Opiate Withdrawal Cocktail: Several companies are working to tackle Opioid withdrawal symptoms developing novel therapies and repurposing existing ones by making an opiate withdrawal cocktail therapy. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 


        

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

Loading...

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Loading...
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – admin@techilive.in. The content will be deleted within 24 hours.
Leave a comment